Exelixis (EXEL)
(Delayed Data from NSDQ)
$40.44 USD
+1.30 (3.32%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $40.47 +0.03 (0.07%) 5:54 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Exelixis, Inc. has a PEG ratio of 0.79 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.65.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EXEL 40.44 +1.30(3.32%)
Will EXEL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for EXEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EXEL
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Do Options Traders Know Something About Exelixis Stock We Don't?
EXEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report?
Why Is Exelixis (EXEL) Up 3.8% Since Last Earnings Report?
Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?
Other News for EXEL
Exelixis earns new Buy at Goldman Sachs on lead candidate
Goldman Sachs Initiates Coverage on Exelixis (EXEL) with a 'Buy' Rating | EXEL Stock News
Netflix upgraded, Five Below initiated: Wall Street’s top analyst calls
Netflix upgraded, Five Below initiated: Wall Street's top analyst calls
Exelixis: Strong Growth Potential with Promising Zanzalintinib Outlook and Attractive Investment Opportunity